Side-by-side · Research reference

PEG-MGFvsTestagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED2/69 cited

BAnimal-MechanisticHUMAN-REVIEWED11/41 cited

PEG-MGF

IGF-1Ec Splice Variant · PEGylated

~2 hrHalf-life (PEG)

~7 minNative MGF t½

IGF-1EcSplice variant

SQ · Research Protocol

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

01Mechanism of Action

Parameter

PEG-MGF

Testagen

Primary target

IGF-1 receptor on muscle satellite cells and myocytes

Testicular tissue; proposed nuclear DNA interaction

Pathway

IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

Downstream effect

Satellite cell activation, muscle fiber repair, localized hypertrophy signaling

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Feedback intact?

Partially bypassed — does not require hepatic IGF-1 synthesis

Unknown — no HPG axis data

Origin

IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Antibody development

Unknown — no long-term human immunogenicity data

—

02Dosage Protocols

Parameter

PEG-MGF

Testagen

Research dose range

100–200 mcg

Extrapolated from animal models; no validated human protocols.

—

Frequency

Post-training or daily

Timing to match endogenous MGF pulse post-exercise.

Once daily or alternate days

Half-life

~2 hours (PEGylated)

Native MGF: ~7 min; PEGylation extends circulation.

Unknown — likely minutes (short peptide)

Evidence basis

Animal / mechanistic

Animal mechanistic / in vitro onlyFedoreyeva 2011

Reconstitution

Sterile bacteriostatic water

Lyophilized form; store reconstituted at 2–8 °C.

Sterile water or bacteriostatic saline

PEG molecular weight

Typically 5–30 kDa

Higher MW = longer t½, greater steric hindrance.

—

Timing

Within 30–60 min post-training

Aligns with endogenous MGF window.

—

Typical protocol (anecdotal)

—

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

Cycle length

—

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

Route

—

Subcutaneous

03Metabolic / Fat Loss Evidence

Parameter

PEG-MGF

Testagen

Primary target

Muscle tissue (satellite cells, myocytes) — not adipose-specific

—

Indirect metabolic effect

IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015

Mechanism distinct from direct lipolytic peptides.

—

Body composition

Lean mass preservation / hypertrophy focus

—

Fat loss evidence

No direct human or animal RCT data for PEG-MGF-driven fat reduction

—

04Side Effects & Safety

Parameter

PEG-MGF

Testagen

Injection site reaction

Erythema, induration (common with SQ peptides)

—

Hypoglycemia risk

IGF-1 axis activation can lower blood glucose

—

IGF-1R overstimulation

Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure

—

Fluid retention

Possible with IGF-1 pathway activation (dose-dependent)

—

PEG accumulation

Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment

—

Antibody formation

PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)

—

Cancer risk

IGF-1 axis stimulation contraindicated in active malignancy

—

Human safety data

Absent — no published human trials for PEG-MGF

—

Injection site reactions

—

Erythema, mild irritation (potential)

Systemic effects

—

Unknown — no human safety data

Hormonal impact

—

No published data on testosterone, LH, FSH effects

Long-term safety

—

Unknown — no long-term studies

Absolute Contraindications

PEG-MGF

·Active malignancy or history of cancer (IGF-1R proliferative signaling)
·Known hypersensitivity to PEGylated compounds
·Pregnancy / lactation (no reproductive toxicity data)

Testagen

·Active testicular malignancy

Relative Contraindications

PEG-MGF

·Diabetes (monitor glucose closely)
·Renal impairment (PEG clearance reduced)
·Retinopathy (IGF-1 axis effects on vascular proliferation)

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

05Administration Protocol

Parameter

PEG-MGF

Testagen

1. Reconstitution

Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

3. Timing

Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

4. Storage

Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

5. Needle

29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.

06Stack Synergy

PEG-MGF

+ BPC-157

Moderate

View BPC-157 →

BPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.

PEG-MGF: 100–200 mcg SQ post-training
BPC-157: 250–500 mcg SQ or oral, twice daily
Duration: 4–6 weeks (injury-dependent)
Primary benefit: Accelerated muscle and connective tissue repair, enhanced recovery

+ TB-500

Strong

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.

PEG-MGF: 100–200 mcg SQ post-training
TB-500: 2–5 mg SQ, 2× per week (loading), then weekly
Timing: Stagger injections by 6–12 hours
Primary benefit: Maximal satellite cell recruitment and myogenic differentiation, injury repair

Testagen

— no documented stacks